Newsletter sign-up

European Wound Management Association
Wednesday, 3 May 2017

We are looking forward to EWMA in Amsterdam and will be attending for the whole conference from 3rd to 5th May 2017.

  • Reapplix announces new US FDA 510(k) clearance for expanded system, including automated centrifuge, a further advancement of its regenerative wound care technology

    Reapplix today announced that it has received US FDA 510(k) clearance for its 3C Patch System® including the 3C Patch Centrifuge.

    This new 510(k) clearance expands the 3C Patch System® to include Reapplix’s new 3C Patch Centrifuge, which features optical sensors and automates the process of producing a 3C Patch®. This further improves usability as health care professionals now need just a few minutes’ hands on time to prepare the 3C Patch. The proprietary 3C Patch Centrifuge further enhances the simple-to-use 3C Patch® device technolog.

  • New clinical trial to evaluate LeucoPatch® in the treatment of malleoli ulcers

    Reapplix today announced that it is funding a new clinical study for LeucoPatch®, on the healing of ulcers on the malleoli, a bony prominence on the ankle, which are often very hard-to-heal, due to the thin layer of tissue over this area.

    LeucoPatch® improves wound healing by concentrating cells and growth factors from the patient’s own blood and applying them to their wounds. Through this, LeucoPatch® is able to accelerate healing and improve clinical outcomes.

    The LiDMUS (LeucoPatch® in Diabetic Malleoli Ulcer Study) study will evaluate both the effect of LeucoPatch® on wound healing and the effect on the local wound environment.

  • Reapplix confirms new funds raised

    Reapplix today announced that it has successfully closed a new funding round of €2.7 million. This new funding was provided by the existing investors, SEED Capital Denmark, Novo Seeds and Vækstfonden (The Danish Growth Fund).

    The new funding will be used to provide continuing forward momentum to the final stages of pre-revenue value creation through to 2018, when Reapplix intends to raise further growth capital in order to undertake the full commercial launch of its lead product, LeucoPatch®.

  • LeucoPatch® Trial to continue following Interim Analysis

    Reapplix today announced that it has been informed by the Trial Steering Committee for the ongoing LeucoPatch® Randomized Controlled Trial (ClinicalTrials.gov NCT02224742) that a planned interim analysis has been performed. The purpose of the planned interim analysis was to re-estimate the sample size (up to 352 patients if needed) or to stop for futility. Following the planned interim analysis, Reapplix has been informed that the trial will continue to the originally estimated sample size of 250 participants.

  • Reapplix receives US FDA 510(k) clearance

    Reapplix today announced that it has received US FDA 510(k) clearance for its 3C Patch System™.

    Reapplix’s proprietary simple-to-use device technology has been cleared for the following indications for use: “The 3C Patch System™ is intended to be used at point-of-care for the safe and rapid preparation of platelet-rich plasma (PRP) gel from a small sample of a patient’s own peripheral blood. Under the supervision of a healthcare professional, the PRP gel produced by the 3C Patch System™ is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers and mechanically or surgically-debrided wounds.”

  • New paper published studying the impact of LeucoPatch in chronic wounds

    A new paper has been published in Clinical & Experimental Immunology. As each LeucoPatch contains a substantial number of leucocytes, the aim of the study was to investigate the activity of the polymorphonuclear neutrophils (PMNs) within the LeucoPatch.

  • Key patents granted in Europe and Eurasia

    Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in Europe and in Eurasia.

  • Patent news – Patent granted in Japan

    Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that a key patent has been granted in the Japan.

  • Patent news – Patents granted in China and Canada

    Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification of key patents grants in China and Canada.

  • Study Shows Effectiveness of LeucoPatch in Healing Diabetic Foot Ulcers

    A newly published study using LeucoPatch, a unique active wound therapy, developed by Reapplix ApS (Reapplix), has been published showing that LeucoPatch was highly effective in healing diabetic foot ulcers.

Page 1 of 2 Next
Top